Boston Scientific Corporation (BSX)
NYSE: BSX · Real-Time Price · USD
99.74
+1.18 (1.20%)
At close: Jun 13, 2025, 4:00 PM
99.77
+0.03 (0.03%)
After-hours: Jun 13, 2025, 7:59 PM EDT
Boston Scientific Revenue
Boston Scientific had revenue of $4.66B in the quarter ending March 31, 2025, with 20.93% growth. This brings the company's revenue in the last twelve months to $17.55B, up 19.36% year-over-year. In the year 2024, Boston Scientific had annual revenue of $16.75B with 17.61% growth.
Revenue (ttm)
$17.55B
Revenue Growth
+19.36%
P/S Ratio
8.37
Revenue / Employee
n/a
Employees
n/a
Market Cap
147.56B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.75B | 2.51B | 17.61% |
Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BSX News
- 4 days ago - 20 stocks bucking bad trends on Wall Street — what might be next for them? - Market Watch
- 8 days ago - 3 Growth Stocks That Aren't the Magnificent 7 - Barrons
- 15 days ago - Boston Scientific: Old, Reliable; Buy For Their Consistent Growth - Seeking Alpha
- 16 days ago - Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook - Benzinga
- 17 days ago - Boston Scientific Corporation (BSX) Bernstein 41st Annual Strategic Decisions Conference (Transcript) - Seeking Alpha
- 17 days ago - Boston Scientific to not seek US approval for heart device amid regulatory challenges - Reuters
- 4 weeks ago - Boston Scientific Corporation (BSX) Bank of America's 2025 Health Care Conference (Transcript) - Seeking Alpha
- 6 weeks ago - Boston Scientific announces upcoming investor conference schedule - PRNewsWire